Latest news with #UroLift
The Hindu
21-05-2025
- Health
- The Hindu
High-risk patient relieved of BPH through minimally invasive procedure
The Asian Institute of Nephrology and Urology (AINU), Visakhapatnam, successfully performed the UroLift procedure on a 72-year-old man with a history of heart problems, chronic obstructive pulmonary disease (COPD), and long-term catheter use due to benign prostatic hyperplasia (BPH). The patient had previously undergone several failed attempts to remove the catheter. Given his high cardiac and anaesthetic risk, G. Ravindra Varma, managing director and senior consultant urologist, chose the UroLift system — a minimally invasive procedure — which he safely performed under local anaesthesia. He was joined by Amit Saple, executive director and senior consultant urologist, and P. Sridhar, consultant urologist, in executing the intervention. The UroLift system uses tiny implants to lift and hold the enlarged prostate tissue away from the urethra, thereby restoring normal urine flow without cutting or removing tissue. After the procedure, the patient was able to void spontaneously and is now catheter-free, significantly improving his comfort and quality of life, according to a statement issued by the hospital.
Yahoo
12-05-2025
- Business
- Yahoo
Teleflex Announces Quarterly Dividend
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy Development in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-04-2025
- Business
- Yahoo
Teleflex to Present at the BofA Securities 2025 Health Care Conference
WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX), will be presenting at the BofA Securities 2025 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Wednesday, May 14, 2025, at 1:40 p.m. (PT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, QuikClot™, LMA™, Pilling™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy
Yahoo
17-04-2025
- Business
- Yahoo
Teleflex Announces First Quarter 2025 Earnings Conference Call Information
WAYNE, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 1, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Contacts: Teleflex Incorporated: Lawrence Keusch Vice President, Investor Relations and Strategy Development in to access your portfolio
Reuters
27-02-2025
- Business
- Reuters
Medical device maker Teleflex to split lower growth units
Feb 27 (Reuters) - Medical equipment maker Teleflex (TFX.N), opens new tab said on Thursday it would split into two companies, retaining three of its segments along with its recently acquired $800 million business, while separating its slower-growing divisions. Shares of the company were down 12% in premarket trade after it also forecast its adjusted profit below Wall Street estimates. After the split, Teleflex would focus on devices for bloodstream and heart procedures, along with medical imaging, while separating its urology, acute care and OEM units. The urology unit has been experiencing lower sales from its UroLift device for enlarged prostate treatment, while the OEM or the contract instrument manufacturing division recently lost a customer. A total of 12 out of 19 manufacturing facilities will be transferred to the new company. Teleflex also plans to boost the remaining business by buying Germany-based Biotronik's blood vessel device unit for about 760 million euros ($796.3 million) in cash. It said the separation will allow each company to simplify operations, streamline manufacturing, allocate resources more effectively and increase management focus. Liam Kelly will stay as Teleflex CEO, and the company intends to initiate an executive search for key management positions at the spun-off business shortly. Teleflex said it would distribute shares of the spun-off company to shareholders and expects the separation to be completed in mid-2026. Separately, the Wayne, Pennsylvania-based company expects adjusted per-share profit for 2025 in the range of $13.95 to $14.35, below analysts' average estimate of $15.23 as per data compiled by LSEG. The company also said its Chief Financial Officer Thomas Powell will retire, and be replaced by accounting chief John Deren. ($1 = 0.9544 euros) Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
